type2 diabetes mellitus(DM)
Conditions
Interventions
SGLT2 inhibitor
DPP4 inhibitor
Sponsors
Dokkyo Medical University Saitama Medical Center Department of Diabetes, Endocrinology and Hematology
Dokkyo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Obese T2DM patients(age 20-75) 2)Drug-naive patients or those to whom oral hypoglycemic agents have been discontinued more than 1 year before consent. 3) The outpatients of Dokkyo Medical University Saitama Medical Center. 4) Patients for whom consent is obtained in writing to be enrolled in the current study.
Exclusion criteria
Exclusion criteria: 1) The patients treated with oral hypoglycemic agents currently or within one year. 2) Patients who are pregnant or may be pregnant. 3)Patients with serious complications such as heart diseases, liver diseases, and kidney disorder. 4) Patients judged to be inappropriate as a participant by doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c (up to 12 months from the start of administration) | — |
Secondary
| Measure | Time frame |
|---|---|
| BP. BW, BMI, sCPR, CBC, AST,ALT, gGTP, TP, Cr, BUN, UA,Na, K, Cl, FBS, T-Chol, HDL-C, LDL-C, TG, Ketone bodies, urine(u)-glucose , u-occult blood, u-ketone bodies. | — |
Countries
Japan
Contacts
Public ContactKoshi Hashimoto
Dokkyo Medical University Saitama Medical Center Department of Diabetes, Endocrinology and Hematology
Outcome results
None listed